Medical research often uncovers unexpected connections, and a recent study from Finland has revealed one that could reshape cancer care. Scientists have discovered that drugs commonly used to treat anemia in patients with chronic kidney disease may also have the potential to slow tumor growth and interfere with cancer progression.
The findings suggest that a class of medications known as HIF-prolyl hydroxylase inhibitors (HIF-PHIs) could one day provide a dual benefit—helping patients manage anemia while simultaneously supporting cancer treatment.
Understanding HIF-PHIs
HIF-PHIs are currently approved for treating anemia associated with chronic kidney disease. These medications work by stabilizing proteins called hypoxia-inducible factors (HIFs), which help the body respond to low oxygen levels. By activating this pathway, the drugs stimulate the production of red blood cells and improve oxygen delivery throughout the body.
Because anemia is a common complication in kidney disease, HIF-PHIs have become an important therapeutic option for improving patients’ quality of life.
The Surprising Cancer Connection
The new study, led by researchers from the University of Oulu and the University of Eastern Finland, found that HIF-PHIs may have effects far beyond treating anemia.
In laboratory experiments, the drugs were shown to:
- Suppress cell growth
- Reduce angiogenesis (the formation of new blood vessels)
- Alter cellular metabolism
- Influence biological pathways involved in tumor development
Angiogenesis is particularly important in cancer because tumors rely on new blood vessels to receive oxygen and nutrients. By limiting this process, HIF-PHIs may make it harder for tumors to grow and spread.
A Discovery That Challenges Existing Knowledge
One of the most intriguing findings was that the anti-cancer effects occurred even when key oxygen-sensing proteins, HIF-1α and HIF-2α, were absent.
This was unexpected because HIF-PHIs were originally designed to work through these proteins. The results suggest that the drugs may activate previously unknown biological mechanisms, opening up entirely new areas of research.
According to the researchers, these findings challenge current understanding of how HIF-PHIs function and highlight the complexity of their effects within the body.
Why This Matters for Cancer Patients
Anemia is one of the most common complications experienced by cancer patients. It can result from:
- The cancer itself
- Chemotherapy treatments
- Radiation therapy
- Chronic inflammation
- Nutritional deficiencies
Currently, anemia management and cancer treatment are often handled separately. If future studies confirm the anti-cancer potential of HIF-PHIs, these medications could offer a more integrated approach.
Potential benefits may include:
Improved Red Blood Cell Production
Patients could experience relief from anemia-related symptoms such as fatigue, weakness, and shortness of breath.
Reduced Tumor Growth
The drugs’ ability to suppress angiogenesis and cell proliferation could help limit cancer progression.
Better Treatment Outcomes
Researchers believe HIF-PHIs could potentially enhance the effectiveness of conventional chemotherapy when used in combination.
Enhanced Quality of Life
Addressing both anemia and cancer simultaneously could reduce treatment burden and improve overall patient well-being.
What Experts Are Saying
Professor Thomas Kietzmann, who led the research, suggests that combining HIF-PHIs with standard cancer therapies may improve outcomes for patients dealing with both cancer and anemia.
The research team is now seeking collaborations with oncologists and clinical investigators to launch studies involving cancer patients suffering from tumor-related anemia.
Important Limitations
While the findings are exciting, it is important to note that the current evidence comes from laboratory studies. Researchers have not yet demonstrated that these anti-cancer effects occur in human patients.
Before HIF-PHIs can be considered part of cancer treatment, several questions must be answered:
- Are the drugs safe for cancer patients?
- Which cancer types might benefit most?
- What dosage would be most effective?
- How do they interact with chemotherapy and immunotherapy?
- Can the laboratory findings be replicated in clinical trials?
Only carefully designed human studies can provide these answers.
Looking Ahead
Drug repurposing—finding new uses for existing medications—is one of the most promising strategies in modern medicine. Because HIF-PHIs are already approved for anemia treatment, researchers may be able to move more quickly toward clinical testing than they would with an entirely new drug.
If future trials confirm the laboratory results, HIF-PHIs could become a valuable addition to cancer care, offering a unique opportunity to address both anemia and tumor progression with a single therapeutic approach.
Conclusion
The discovery that anemia drugs may possess anti-cancer properties represents an exciting step forward in oncology research. By reducing tumor-supporting blood vessel formation and suppressing cell growth, HIF-PHIs could potentially serve a dual role in treating cancer patients who also suffer from anemia.
Although clinical validation is still needed, the study highlights how existing medicines can reveal unexpected therapeutic potential. As researchers continue to investigate these findings, HIF-PHIs may emerge as an innovative tool in the fight against cancer—improving both treatment outcomes and patient quality of life.
The study was published in the journal Redox Biology and was supported by the Research Council of Finland and the Jane and Aatos Erkko Foundation.
Recommended Products
